Elkedonia Named an “Emerging Company” by BioCentury for Pioneering Psychiatry

BioCentury has selected Elkedonia as a featured “Emerging Company” validating its first-in-class approach targeting the ELK1 protein to treat depression without hallucinogenic side effects. This recognition highlights Elkedonia’s unique ability to drive neuroplasticity downstream of neurotransmitters, positioning it at the forefront of precision neuropsychiatry.